NLRP3 and atherosclerosis: Separately, in vitro and in a mouse model of atherosclerosis, miR-155 was implicated in promoting an ox-LDL-ERK1-NLRP3 signaling axis that worsened atherosclerotic inflammasome activation and worsened plaque formation—which could be selectively reversed with the ERK inhibitor U0126 [37].